Legend Announces FDA Clearance of IND Application on CAR-T Immuno-cell Therapy for the Treatment of Multiple Myeloma

LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen PISCATAWAY, N.J., May 30, 2018 -- (Healthcare Sales & Marketing Network) -- Legend Biotech, a subsidiary of GenScript Biotech Corporation... Biopharmaceuticals, Oncology, FDA Legend Biotech, GenScript Biotech, Janssen, CAR-T therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news